Taysha Gene Therapies granted two new employees options to purchase 212,000 shares of the company's stock on Dec 3, 2025.
On December 3, 2025, Taysha Gene Therapies, Inc. disclosed that the Compensation Committee of its Board of Directors awarded two new employees a total of 212,000 stock options as part of their employment agreement. These options allow the employees to buy shares of the Company's common stock. The grants were issued under the Taysha Gene Therapies, Inc. 2023 Inducement Plan to attract key talent, in line with Nasdaq Listing Rule 5635(c)(4). Taysha is a clinical-stage biotech firm specializing in AAV-based gene therapies for severe monogenic CNS diseases. Taysha is listed on the Nasdaq under the ticker symbol TSHA.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments